Penumbra CEO Adam Elsesser sells $4.37 million in stock

Published 31/05/2025, 01:08
Penumbra CEO Adam Elsesser sells $4.37 million in stock

Adam Elsesser, the CEO and President of Penumbra Inc . (NYSE:PEN), a healthcare company with a market capitalization of $10.32 billion and strong year-to-date returns of 12.4%, executed a series of stock transactions on May 28, 2025, according to a recent SEC filing. Based on InvestingPro analysis, the stock appears to be trading above its Fair Value. Elsesser sold a total of 16,099 shares of Penumbra common stock, amounting to a total value of approximately $4.37 million. The sales were conducted at prices ranging from $263.42 to $273.40 per share, as part of a Rule 10b5-1 trading plan. The company maintains robust financial health with a current ratio of 6.3, indicating strong liquidity.

In addition to the stock sales, Elsesser also exercised stock options to acquire 27,976 shares at an exercise price of $30 per share, equivalent to a total value of $839,280. For deeper insights into Penumbra’s valuation metrics and 12+ exclusive ProTips, consider exploring InvestingPro. Following these transactions, Elsesser holds 98,289 shares of Penumbra stock directly and an additional 577,582 shares indirectly through a trust.

In other recent news, Penumbra reported strong financial results, with sales reaching $324.1 million, a 16.3% increase from the previous year, and earnings per share (EPS) rising to $0.83, a 102.8% jump. These figures surpassed Wall Street estimates, with UBS raising its price target for Penumbra to $330, maintaining a Buy rating. Stifel also increased its price target to $318, highlighting Penumbra’s performance in the U.S. Thrombectomy market, which saw a 25% year-over-year revenue increase. BTIG followed suit, raising its price target to $320, praising the company’s significant revenue growth in the Thrombectomy segment and strong gross and operating margins.

Additionally, Piper Sandler analyst Matt O’Brien suggested that Penumbra’s Thunderbolt product might receive regulatory approval sooner than expected, potentially boosting the company’s revenue further. The anticipation of this early approval has not been factored into current financial projections, offering potential upside for Penumbra. Investors are closely watching the Thunderbolt’s progress, as its approval could enhance Penumbra’s competitive position in the medical device sector. Penumbra’s strategic focus on the U.S. market and its domestic manufacturing base have contributed to its favorable outlook.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.